Skip to main content

Peer Review reports

From: A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society

Original Submission
17 Nov 2021 Submitted Original manuscript
29 Dec 2021 Reviewed Reviewer Report
6 Feb 2022 Reviewed Reviewer Report
9 Feb 2022 Reviewed Reviewer Report
26 Mar 2022 Author responded Author comments - Ji-Bin Li
Resubmission - Version 2
26 Mar 2022 Submitted Manuscript version 2
10 Apr 2022 Reviewed Reviewer Report
28 Apr 2022 Reviewed Reviewer Report
12 Jun 2022 Author responded Author comments - Ji-Bin Li
Resubmission - Version 3
12 Jun 2022 Submitted Manuscript version 3
11 Jul 2022 Author responded Author comments - Ji-Bin Li
Resubmission - Version 4
11 Jul 2022 Submitted Manuscript version 4
1 Aug 2022 Reviewed Reviewer Report
4 Aug 2022 Author responded Author comments - Ji-Bin Li
Resubmission - Version 5
4 Aug 2022 Submitted Manuscript version 5
Publishing
4 Aug 2022 Editorially accepted
26 Sep 2022 Article published 10.1186/s12916-022-02516-9

You can find further information about peer review here.

Back to article page